Zymeworks Inc.

Zymeworks Inc.

Developing novel medicines for patients with difficult-to-treat cancers and other serious diseases.

Founded 2003 Canada

Canada 264 employees IPO Total: $867.80M Biotechnology, Health and Wellness

Zymeworks Inc. is a seasoned player in the biotechnology and health and wellness industries, founded in 2003 and headquartered in Canada. The company is committed to innovating medicine development for hard-to-treat cancers and serious diseases, as reflected in their slogan: "Developing novel medicines for patients with difficult-to-treat cancers and other serious diseases."

Zymeworks stands out due to its proprietary antibody engineering platforms that fuel a diverse product pipeline, including multispecific antibodies and antibody-drug conjugates. Highlighting its specialized therapeutic advancements, the company also manages partnered programs such as Ziihera® (zanidatamab-hrii). With an integrated R&D setup, the firm has successfully forged strategic alliances to target significant unmet medical needs.

Recent developments saw an impressive $250.00M post-IPO debt investment from Royalty Pharma on 01 March 2026, underscoring investor confidence. This financial backing positions Zymeworks Inc. to further its cutting-edge efforts in biotherapeutics.

Funding Stage	Amount	Investors	Lead Investors	Date
Post-IPO Debt	$250.00M	1	Royalty Pharma	01 Mar 2026
Private Placement VC	$50.00M	1	EcoR1 Capital	01 Dec 2023
Post-IPO Equity	$100.00M	-		01 Jan 2022
Post-IPO Equity	Undisclosed	-		01 Nov 2019
Post-IPO Equity	$201.30M	-		01 Jun 2019
Post-IPO Equity	$97.80M	4	Health Venture, Raymond James +2	01 Jun 2018
IPO	$63.00M	-		01 Apr 2017
Late VC	$61.50M	11	BDC Capital, Brace Pharma Capital +9	01 Jan 2016
Late VC	$1.80M	-		01 Feb 2015
Early VC	$15.00M	2	Celgene, Eli Lilly	01 Jan 2014

Funding Stage

Amount

Investors

Lead Investors

Date

Post-IPO Debt

$250.00M

Royalty Pharma

01 Mar 2026

Private Placement VC

$50.00M

EcoR1 Capital

01 Dec 2023

Post-IPO Equity

$100.00M

01 Jan 2022

Post-IPO Equity

Undisclosed

01 Nov 2019

Post-IPO Equity

$201.30M

01 Jun 2019

Post-IPO Equity

$97.80M

Health Venture, Raymond James +2

01 Jun 2018

IPO

$63.00M

01 Apr 2017

Late VC

$61.50M

BDC Capital, Brace Pharma Capital +9

01 Jan 2016

Late VC

$1.80M

01 Feb 2015

Early VC

$15.00M

Celgene, Eli Lilly

01 Jan 2014

FAQ About Zymeworks Inc.

Developing novel medicines for patients with difficult-to-treat cancers and other serious diseases.

Zymeworks Inc. was founded in 2003.

Zymeworks Inc. is headquartered in Canada.

Zymeworks Inc. operates in Biotechnology and Health and Wellness. Its work centres on antibody therapeutics, cancer treatment, autoimmune diseases and inflammatory diseases. Its customers include Patients with difficult-to-treat diseases, Healthcare providers and Pharmaceutical companies.

Zymeworks Inc. has a B2B, B2B2B and White Label business model. Its revenue comes from Licensing and Performance Based.

Zymeworks Inc. has approximately 264 employees.

Zymeworks Inc. has completed 17 funding rounds, raising a total of $867.80M. The latest funding stage is IPO.

Zymeworks Inc. offers: Development of novel medicines, Antibody drug creation, Pipeline management, Partnership and collaboration in drug development.

Top alternatives and competitors to Zymeworks Inc. include Antharis Therapeutics, Inc., Oxford BioTherapeutics, Attovia Therapeutics, Enlaza Therapeutics, Santa Ana Bio, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Zymeworks Inc. and Antharis Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Zymeworks Inc.

Services & Products

Target Customers

Funding Rounds & Investors (17)

Zymeworks Inc. Alternatives & Competitors

FAQ About Zymeworks Inc.